Phase 2
N=54
fMRI Study Examining Effects of D-cycloserine in Specific Phobia
Phobias
Bottom Line
View on ClinicalTrials.gov: NCT00591825 ↗Enrolled (actual)
54
Serious AEs
0.0%
Results posted
Jun 2017
Primary outcome: Primary: fMRI Brain Activations During Symptom Provocation — .200; .157; -.013; .036 percent signal change
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- D-cycloserine (Drug); Placebo (Drug)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Kansas Medical Center
- Primary completion
- Dec 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY fMRI Brain Activations During Symptom Provocation |
.200; .157; -.013; .036; .012; .021 | — |
| SECONDARY Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests) |
51.93; 49; 52.69; 52.93; 34.36; 32.46 | — |
| SECONDARY Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT) |
4.93; 4.92; 3.69; 4.14; 34.68; 34.46 | — |
| SECONDARY Cognitive Functioning Measured Using the Iowa Gambling Test |
44.29; 32.62; 28.58; 21.85 | — |
| SECONDARY Cognitive Functioning Measured Using the Wisconsin Card Sorting Task |
13.29; 13.62; 18.23; 15.67 | — |
Summary
The research team hopes to use brain imaging and mental testing to learn more about specific phobias and the treatment of phobia. When given directly prior to therapy sessions, D-cycloserine has been shown to enhance the effects of therapy. This study hopes to identify reasons why D-cycloserine has this effect by measuring brain activity.
Eligibility Criteria
Inclusion Criteria
- Right-handed
- Adults between 18 and 55 years of age
- Subjects in the phobic group will additionally meet diagnostic (DSM-IV) criteria for spider phobia.
- Individuals of both genders and all races will be included
Exclusion Criteria
- Women who are breastfeeding or pregnant
- Individuals with medical conditions unsuitable for MR scanning
- Individuals reporting a history of epilepsy or seizures
- Individuals reporting an allergy to cycloserine
- Individuals diagnosed with asthma or who report previous anaphylactic reaction to insect stings/bites, medication, food, or other material and/or event
- Individuals reporting present or past diagnosis of a developmental disorder, neurological disorder, or head injury *Individuals found to have Axis I psychopathology as defined by the DSM-IV (other than spider phobia)
- Individuals currently taking any psychotropic medication
Data sourced from ClinicalTrials.gov (NCT00591825). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.